Our studies underscore the pivotal LVBU-BCL6-p53-UC axis deregulation during tumor development and illustrate the potential of exploiting this axis to control urea cycle/polyamine biosynthesis deregulation for cancer treatment. The gene discussed is BCL6; the disease is neoplasm.